Journal of Cancer Metastasis and Treatment最新文献_第7页

Two sides to colon cancer: mice mimic human anatomical region disparity in colon cancer development and progression. 结肠癌的两面:小鼠模拟人类结肠癌发生和发展的解剖区域差异

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2018-01-01 Epub Date: 2018-09-27 DOI: 10.20517/2394-4722.2018.39

Jessica Felton, Kunrong Cheng, Aaron C Shang, Shien Hu, Shannon M Larabee, Cinthia B Drachenberg, Jean-Pierre Raufman

{"title":"Two sides to colon cancer: mice mimic human anatomical region disparity in colon cancer development and progression.","authors":"Jessica Felton, Kunrong Cheng, Aaron C Shang, Shien Hu, Shannon M Larabee, Cinthia B Drachenberg, Jean-Pierre Raufman","doi":"10.20517/2394-4722.2018.39","DOIUrl":"10.20517/2394-4722.2018.39","url":null,"abstract":"Aim: Strong evidence reveals important differences between cancers in the proximal vs. distal colon. Animal models of metastatic colon cancer are available but with varying degrees of reproducibility and several important limitations. We explored whether there were regional differences in the location of murine colon cancers and assessed the utility of murine models to explore the biological basis for such differences.Methods: We re-analyzed data from our previous studies to assess the regional distribution of murine colon cancer. In survival surgery experiments, we injected HT-29 human colon cancer cells into the wall of the cecum or distal colon of Nu(NCr)-Foxn1nu or NOD.Cg-PrkdcscidIl2rgTim1Wji/SzJ mice and compared the development of primary tumors and metastases.Results: Within 7-17 weeks after intramural cecal injection of HT-29 cells, eight mice failed to develop solid primary tumors or metastases. In contrast, within four weeks after cell injection into the distal colon, 13 mice developed metastases - 12 mice developed subcutaneous metastases; of these, four developed liver metastases and one developed both liver and lung metastases. One mouse developed liver metastases only. Histological examination confirmed these lesions were adenocarcinomas.Conclusion: Our findings reveal the preferential growth of murine colon neoplasia and invasive human orthotopic xenografts in the distal mouse colon. The new approach of injecting cells into the distal colon wall results in a pattern of colon cancer development that closely mimics the progression of metastatic colon cancer in humans. This novel model of colon neoplasia has great potential for exploring anatomical differences in colon cancer and testing novel therapeutics.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"4 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47223058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. 结直肠癌的药物基因组学:目前在临床实践中的作用和未来的展望。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2018-01-01 Epub Date: 2018-03-07 DOI: 10.20517/2394-4722.2018.04

Francesca Battaglin, Alberto Puccini, Madiha Naseem, Marta Schirripa, Martin D Berger, Ryuma Tokunaga, Michelle McSkane, Taline Khoukaz, Shivani Soni, Wu Zhang, Heinz-Josef Lenz

{"title":"Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives.","authors":"Francesca Battaglin, Alberto Puccini, Madiha Naseem, Marta Schirripa, Martin D Berger, Ryuma Tokunaga, Michelle McSkane, Taline Khoukaz, Shivani Soni, Wu Zhang, Heinz-Josef Lenz","doi":"10.20517/2394-4722.2018.04","DOIUrl":"10.20517/2394-4722.2018.04","url":null,"abstract":"The treatment scenario of colorectal cancer (CRC) has been evolving in recent years with the introduction of novel targeted agents and new therapeutic strategies for the metastatic disease. An extensive effort has been directed to the identification of predictive biomarkers to aid patients selection and guide therapeutic choices. Pharmacogenomics represents an irreplaceable tool to individualize patients treatment based on germline and tumor acquired somatic genetic variations able to predict drugs response and risk of toxicities. The growing knowledge of CRC molecular characteristics and complex genomic makeup has played a crucial role in identifying predictive pharmacogenomic biomarkers, while supporting the rationale for the development of new drugs and treatment combinations. Clinical validation of promising biomarkers, however, is often an issue. More recently, a deeper understanding of resistance mechanisms and tumor escape dynamics under treatment pressure and the availability of novel technologies are opening new perspectives in this field. This review aims to present an overview of current pharmacogenomic biomarkers and future perspectives of pharmacogenomics in CRC, in an evolving scenario moving from a single drug-gene interactions approach to a more comprehensive genome-wide approach, comprising genomics and epigenetics.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"4 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39425912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Using circulating tumor cells to advance precision medicine in prostate cancer. 利用循环肿瘤细胞推进前列腺癌精准医疗。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2017-01-01 Epub Date: 2017-09-27 DOI: 10.20517/2394-4722.2017.45

Giuseppe Galletti, Daniel Worroll, David M Nanus, Paraskevi Giannakakou

{"title":"Using circulating tumor cells to advance precision medicine in prostate cancer.","authors":"Giuseppe Galletti, Daniel Worroll, David M Nanus, Paraskevi Giannakakou","doi":"10.20517/2394-4722.2017.45","DOIUrl":"10.20517/2394-4722.2017.45","url":null,"abstract":"The field of CTC enrichment has seen many emerging technologies in recent years, which have resulted in the identification and monitoring of clinically relevant, CTC-based biomarkers that can be analyzed routinely without invasive procedures. Several molecular platforms have been used to investigate the molecular profile of the disease, from high throughput gene expression analyses down to single cell biological dissection. The established presence of CTC heterogeneity nevertheless constitutes a challenge for cell isolation as the several subpopulations can potentially display different molecular characteristics; in this scenario, careful consideration must be given to the isolation approach, whereas methods that discriminate against certain subpopulations may result in the exclusion of CTCs that carry biological relevance. In the context of prostate cancer (PC), CTC molecular interrogation can enable longitudinal monitoring of key biological features during treatment with substantial clinical impact, as several biomarkers could predict tumor response to AR signaling inhibitors (abiraterone, enzalutamide) or standard chemotherapy (taxanes). Thus, CTCs represent a valuable opportunity to personalize medicine in current clinical practice.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"3 ","pages":"190-205"},"PeriodicalIF":1.9,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913755/pdf/nihms958394.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36054679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells. TGF-β刺激EMT程序引发乳腺癌细胞的非基因组ER-α活性和抗雌激素抵抗

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2017-01-01 Epub Date: 2017-08-21 DOI: 10.20517/2394-4722.2017.38

Maozhen Tian, William P Schiemann

{"title":"TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells.","authors":"Maozhen Tian, William P Schiemann","doi":"10.20517/2394-4722.2017.38","DOIUrl":"https://doi.org/10.20517/2394-4722.2017.38","url":null,"abstract":"Aim: Estrogen receptor-α (ER-α) activation drives the progression of luminal breast cancers. Signaling by transforming growth factor-β (TGF-β) typically opposes the actions of ER-α; it also induces epithelial-mesenchymal transition (EMT) programs that promote breast cancer dissemination, stemness, and chemoresistance. The impact of EMT programs on nongenomic ER-α signaling remains unknown and was studied herein.Methods: MCF-7 and BT474 cells were stimulated with TGF-β to induce EMT programs, at which point ER-α expression, localization, and nongenomic interactions with receptor tyrosine kinases and MAP kinases (MAPKs) were determined. Cell sensitivity to anti-estrogens both before and after traversing the EMT program was also investigated.Results: TGF-β stimulated MCF-7 and BT474 cells to acquire EMT phenotypes, which enhanced cytoplasmic accumulation of ER-α without altering its expression. Post-EMT cells exhibited (i) elevated expression of EGFR and IGF1R, which together with Src formed cytoplasmic complexes with ER-α; (ii) enhanced coupling of EGF, IGF-1 and estrogen to the activation of MAPKs; and (iii) reduced sensitivity to tamoxifen, an event reversed by administration of small molecule inhibitors against the receptors for TGF-β, EGF, and IGF-1, as well as those against MAPKs.Conclusion: EMT stimulated by TGF-β promotes anti-estrogen resistance by activating EGFR-, IGF1R-, and MAPK-dependent nongenomic ER-α signaling.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":"3 ","pages":"150-160"},"PeriodicalIF":1.9,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612668/pdf/nihms905795.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35394501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 41

DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression. DNA 损伤诱导的核因子-kappa B 激活及其在癌症进展中的作用。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2017-01-01 Epub Date: 2017-03-27 DOI: 10.20517/2394-4722.2017.03

Wei Wang, Arul M Mani, Zhao-Hui Wu

引用次数: 0

Muscarinic receptor signaling and colon cancer progression. 毒蕈碱受体信号传导与结肠癌进展

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2016-06-15 DOI: 10.20517/2394-4722.2016.05

Guofeng Xie, Jean-Pierre Raufman

引用次数: 0